Page 49 - ஒன்றுபட்டது மாநிலங்களில் கம்பி குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Viewpoint Molecular Targetin(TM) Commences Patient Enrollment in Phase 1 Imaging Study for VMT01 Program for Metastatic Melanoma ACCESSWIRE 11 Jun 2021, 00:05 GMT+10 - VMT01 Phase 1 imaging study followed by Phase 1/2a therapy study for the treatment of metastatic melanoma being conducted at Mayo Clinic - - Positive preclinical data have demonstrated that a single dose of [212Pb]-VMT01 has significantly arrested melanoma tumor growth and extended survival - - VMT01 imaging study provisional results expected in Q4 2021 - CORALVILLE, IA / ACCESSWIRE / June 10, 2021 / Viewpoint Molecular Targeting, Inc. ( Viewpoint or the Company ), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has initiated patient enrollment and screening in its Phase 1 imaging study evaluating VMT01 for the treatment of metastatic melanoma.

United statesJenene thomasFrancesl johnsonViewpoint molecular targeting incAmerican cancer societyMayo clinicViewpoint molecular targetingChief executive officerViewpoint molecularPositron emission tomographySingle photon emission computerized tomographyMolecular targetingUnited states wire groupஒன்றுபட்டது மாநிலங்களில்அமெரிக்கன் புற்றுநோய் சமூகம்மயோ சிகிச்சையகம்